




Patent Docket P0709P1D3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Paul J. Carter et al. Serial No.: 09/705,686 Filed: November 2, 2000 For: METHOD FOR MAKING HUMANIZED ANTIBODIES	Group Art Unit: 1642 Examiner: L. Helms CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to: U.S. Patent and Trademark Office, Washington, D.C. 20231-9999 Express Mail No. EL 889 330-581 US March 18, 2002  Wendy M. Lee
------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

STATEMENT OF RELATED CASES

Assistant Commissioner of Patents
Washington, D.C. 20231


Sir:

The following applications are related to the above-identified application:

- U.S. Application Serial No. 08/146,206, filed November 17, 1993;
- U.S. Application Serial No. 09/115,800, filed July 15, 1998;
- U.S. Application Serial No. 09/366,004, filed August 2, 1999;
- U.S. Application Serial No. 09/705,392, filed November 2, 2000; and
- U.S. Application Serial No. 09/705,398, filed November 2, 2000.

Respectfully submitted,
GENENTECH, INC.

Date: March 18, 2002

By: 
Wendy M. Lee
Reg. No. 40,378
Telephone: (650) 225-1994



09157

PATENT TRADEMARK OFFICE

09/705/686

Sheet 01 of 13
RECEIVED

FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No: P0709P1D3	Serial No: 02/2800 not yet assigned
		Applicant 02 MAR 27 PM 12:58 Paul J. Carter et al.	
		Filing Date 02 Nov 2000	Group not yet assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	*	1 07/984,373		Carter et al.			21.08.92
	*	2 08/437,642		Carter et al.			09.05.95
	*	3 09/115,800		Carter et al.			15.07.98
		4 4,753,894	28.06.88	Frankel et al.			
	*	5 4,816,567	28.03.89	Cabilly et al.			
	*	6 4,845,198	04.07.89	Urdal et al.			
	*	7 5,132,405	21.07.92	Huston et al.			
		8 5,169,774	08.12.92	Frankel et al.			
	*	9 5,225,539	06.07.93	Winter, G.			
	*	10 5,530,101	25.06.96	Queen et al.			19.12.90
	*	11 5,558,864	24.09.96	Bendig et al.			
	*	12 5,585,089	17.12.96	Queen et al.			07.06.95
	*	13 5,677,171	14.10.97	Hudziak et al.			
	*	14 5,714,350	03.02.98	Co et al.			13.01.95
		15 5,720,937	24.02.98	Hudziak et al.			
		16 5,720,954	24.02.98	Hudziak et al.			
		17 5,725,856	10.03.98	Hudziak et al.			
		18 5,770,195	23.06.98	Hudziak et al.			
	*	19 5,772,997	30.06.98	Hudziak et al.			
	*	20 5,821,337	13.10.98	Carter et al.			
	*	21 5,859,205	12.01.99	Adair et al.			07.09.94
		22 6,054,561	25.04.00	Ring			07.06.95

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
	*	23 85058/91	30.03.92	AUSTRALIA				
	*	24 0 460 167 B1	11.12.91	EPO				
	*	25 0 519 596 A1	23.12.92	EPO				
	*	26 0 592 106 A1	13.04.94	EPO				
	*	27 120,694	03.10.84	EPO				
	*	28 125,023 A1	14.11.84	EPO				
	*	29 239,400	30.09.87	EPO				
	*	30 323,806 A1	12.07.89	EPO				
	*	31 328,404 A1	16.08.89	EPO				
	*	32 338,745 A1	25.10.89	EPO				
	*	33 365,209 A2	25.04.90	EPO				

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

09/205,686

FORM PTO-1449 U.S. Dept. of Commerce Patent and Trademark Office LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)	Atty Docket No. P0709P1D3 Applicant Paul J. Carter et al. Filing Date 02 Nov 2000	Serial No. not yet assigned Group not yet assigned
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------

FOREIGN PATENT DOCUMENTS							
Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
	*	34 365,997 A2	02.05.90	EPO			
	*	35 368,684	16.05.90	EPO			
	*	36 403,156 A1	19.12.90	EPO			
	*	37 432,249 B1	25.09.96	EPO			
	*	38 438,310 A2	24.07.91	EPO			
	*	39 440,351	07.08.91	EPO			
	*	40 451,216 B1	24.01.96	EPO			
	*	41 620,276	19.10.94	EPO			
	*	42 682,040 A1	15.11.95	EPO			
	*	43 EP 438,312	24.07.91	EPO			
	*	44 94/11509	26.05.94	PCT			
	*	45 WO 87/02671	07.05.87	PCT			
	*	46 WO 88/09344	01.12.88	PCT			
	*	47 WO 89/01783	09.03.89	PCT			
	*	48 WO 89/06692	27.07.89	PCT			
	*	49 WO 89/09622		PCT			
	*	50 WO 90/07861	26.07.90	PCT			
	*	51 WO 91/07492	30.05.91	PCT			
	*	52 WO 91/07500	30.05.91	PCT			
	*	53 WO 91/09966	11.07.91	PCT			
	*	54 WO 91/09967	11.07.91	PCT			
	*	55 WO 91/09968	11.07.91	PCT			
	*	56 WO 92/01047	23.01.92	PCT			
	*	57 WO 92/04380	19.03.92	PCT			
	*	58 WO 92/04381	19.03.92	PCT			
	*	59 WO 92/05274	02.04.92	PCT			
	*	60 WO 92/11018	07.09.92	PCT			
	*	61 WO 92/11383	09.07.92	PCT			
	*	62 WO 92/15683	17.09.92	PCT			
	*	63 WO 92/16562	01.10.92	PCT			
	*	64 WO 92/22653	23.12.92	PCT			
	*	65 WO 93/02191	04.02.93	PCT			
	*	66 WO 94/12214	09.06.94	PCT			
		67 WO 99/60023	25.11.99	PCT			
	*	68 2 188941	14.10.87	UNITED KINGDOM			

Examiner	Date Considered
----------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

09/705,686

Sheet 03 of 13

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0709P1D3	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Paul J. Carter et al.	
				Filing Date 02 Nov 2000	Group not yet assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	* 69	Adair et al., "Humanization of the murine anti-human CD3 monoclonal antibody OKT3" <u>Hum. Antibod. Hybridomas</u> 5:41-47 (1994)			
	* 70	Amit et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution" <u>Science</u> 233:747-753 (Aug 1986)			
	* 71	Amzel and Poljak, "Three-dimensional structure of immunoglobulins" <u>Ann. Rev. Biochem.</u> 48:961-967 (1979)			
	* 72	Amzel et al., "The Three Dimensional Structure of a Combining Region-Ligand Complex of Immunoglobulin NEW at 3.5-A Resolution" <u>Proc. Natl. Acad. Sci. USA</u> 71(4):1427-1430 (Apr 1974)			
	* 73	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> 14(3):737-744 (Mar 1996)			
	* 74	Beverley & Callard, "Distinctive functional characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody" <u>European Journal of Immunology</u> 11:329-334 (1981)			
	* 75	Bindon et al., "Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q" <u>Journal of Experimental Medicine</u> 168(1):127-142 (July 1988)			
	* 76	"Biosym Technologies" in New Products, Chemical Design Automation 3" (December 1988)			
	* 77	Bird et al., "Single-chain antigen-binding proteins" <u>Science</u> 242:423-426 (Oct 1988)			
	* 78	Boulianne et al., "Production of functional chimaeric mouse/human antibody" <u>Nature</u> 312:643-646 (December 13, 1984)			
	* 79	Brennan et al., "Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G ₁ fragments" <u>Science</u> 229:81-83 (July 1985)			
	* 80	Brown et al., "Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival" <u>Proc. Natl. Acad. Sci. USA</u> 88:2663-2667 (April 1991)			
	* 81	Brown, Jr. et al., "Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival" <u>Proc. Natl. Acad. Sci. USA</u> 88:2663-2667 (1991)			
	* 82	Brucoleri et al., "Structure of antibody hypervariable loops reproduced by a conformational search algorithm" <u>Nature</u> 335:564-568 (Oct 1988)			
	* 83	Brucoleri, "Structure of antibody hypervariable loops reproduced by a conformational search algorithm" <u>Nature</u> 336:266 (1988)			
	* 84	Bruggemann, M. et al., "Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies" <u>Journal of Experimental Medicine</u> 166:1351-1361 (1987)			
	* 85	Burgess et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue" <u>Journal of Cell Biology</u> 111:2129-2138 (1990)			
	* 86	Caron et al., "Biological and Immunological Features of Humanized M195 (Anti-CD33) Monoclonal Antibodies" <u>Cancer Research</u> 52:6761-6767 (Dec 1992)			
	* 87	Carter et al., "High level Escherichia coli expression and production of a bivalent humanized antibody fragment" <u>Bio/Technology</u> 10:163-167 (1992)			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0709P1D3	Serial No. not yet assigned
				Applicant Paul J. Carter et al.	
				Filing Date 02 Nov 2000	
				Group not yet assigned	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
* 88	Carter et al., "Humanization of an anti-p185HER2 antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 89:4285-4289 (May 1992)				
* 89	Casale et al., "Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis" <u>J. Allergy Clin. Immunol.</u> 100:110-121 (1997)				
* 90	Cheetham, J., "Reshaping the antibody combining site by CDR replacement-tailoring or tinkering to fit?" <u>Protein Engineering</u> 2(3):170-172 (1988)				
* 91	Chothia & Lesk, "The relation between the divergence of sequence and structure in proteins" <u>EMBO Journal</u> 5(4):823-826 (1986)				
* 92	Chothia and Lesk, "Canonical structures for the hypervariable regions of immunoglobulins" <u>J. Mol. Biol.</u> 196(4):901-917 (1987)				
* 93	Chothia et al., "Domain Association in Immunoglobulin Molecules. The Packing of Variable Domains" <u>Journal of Molecular Biology</u> 186:651-663 (1985)				
* 94	Chothia et al., "Principles of protein-protein recognition" <u>Nature</u> 256:705-708 (1975)				
* 95	Chothia et al., "The predicted structure of immunoglobulin D1.3 and its comparison with the crystal structure" <u>Science</u> 233:755-758 (Aug. 15, 1986)				
* 96	Chothia et al., "Transmission of conformational change in insulin" <u>Nature</u> 302:500-505 (1983)				
* 97	Chothia, C. et al., "Conformations of immunoglobulin hypervariable regions" <u>Nature</u> 342(6252):877-883 (1989)				
* 98	Clark et al., "The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies" <u>European Journal of Immunology</u> 19:381-388 (1989)				
* 99	Co & Queen, "Humanized antibodies for therapy" <u>Nature</u> 351:501-502 (Jun 1991)				
* 100	Co et al., "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen" <u>J. of Immunology</u> 148(4):1149-1154 (Feb 1992)				
* 101	Co et al., "Humanized Anti-Lewis Y Antibodies: In Vitro Properties and Pharmacokinetics in Rhesus Monkeys" <u>Cancer Research</u> 56:1118-1125 (Mar 1996)				
* 102	Co et al., "Humanized antibodies for antiviral therapy" <u>Proc. Natl. Acad. Sci. USA</u> 88:2869-2873 (April 1991)				
* 103	Colman et al., "Crystal and Molecular Structure of the Dimer of Variable Domains of the Bence-Jones Protein ROY" <u>J. Mol. Biol.</u> 116:73-79 (1977)				
* 104	Colman et al., "Three-dimensional structure of a complex of antibody with influenza virus neuraminidase" <u>Nature</u> 326:358-363 (Mar 1987)				
* 105	Cook et al., "A map of the human immunoglobulin V _H locus completed by analysis of the telomeric region of chromosome 14q" <u>Nature Genetics</u> 7:162-168 (Jun 1994)				
* 106	Corti et al., "Idiotope Determining Regions of a Mouse Monoclonal Antibody and Its Humanized Versions" <u>J. Mol. Biol.</u> 235:53-60 (1994)				
* 107	Coussens et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene" <u>Science</u> 230:1132-1139 (1985)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0709P1D3	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Paul J. Carter et al.	
				Filing Date 02 Nov 2000	Group not yet assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	*108	Couto et al., "Anti-BA46 Monoclonal Antibody Mc3 Humanization Using a Novel Positional Consensus and in Vivo and in Vitro Characterization" <u>Cancer Research Supplement</u> 55:1717-1722 (1995)			
	*109	Couto et al., "Humanization of KC4G3, an Anti-Human Carcinoma Antibody" <u>Hybridoma</u> 13:215-219 (1994)			
	*110	Darsley & Rees, "Nucleotide sequences of five anti-lysozyme monoclonal antibodies" <u>EMBO Journal</u> 4(2):393-398 (1985)			
	*111	Daugherty et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins" <u>Nucleic Acids Research</u> 19(9):2471-2476 (May 11, 1991)			
	*112	Davies & Metzger, "Structural Basis of Antibody Function" <u>Ann. Rev. Immunol.</u> 1:87-117 (1983)			
	*113	Davies et al., "Antibody-Antigen Complexes" <u>Journal of Biological Chemistry</u> 263(22):10541-10544 (Aug. 1988)			
	*114	Davies, D. R. et al., "Antibody-Antigen Complexes" <u>Ann. Rev. Biochem.</u> 59:439-473 (1990)			
	*115	Eigenbrot et al., "X-Ray Structures of Fragments From Binding and Nonbinding Versions of a Humanized Anti-CD18 Antibody: Structural Indications of the Key Role of V _H Residues 59 to 65" <u>Proteins: Structure, Function, and Genetics</u> 18:49-62 (1994)			
	*116	Eigenbrot et al., "X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling" <u>J. Mol. Biol.</u> 229:969-995 (1993)			
	*117	Ellis et al., "Engineered Anti-CD38 Monoclonal Antibodies for Immunotherapy of Multiple Myeloma" <u>The Journal of Immunology</u> pps. 925-937 (1995)			
	*118	Ellison et al., "The nucleotide sequence of a human immunoglobulin C _γ 1 gene" <u>Nucleic Acids Research</u> 10(13):4071-4079 (1982)			
	*119	Emery & Adair, "Humanised monoclonal antibodies for therapeutic applications" <u>Exp. Opin. Invest. Drugs</u> 3(3):241-251 (1994)			
	*120	Epp et al., "Crystal and Molecular Structure of a Dimer Composed of the Variable Portions of the Bence-Jones Protein REI" <u>European Journal of Biochemistry</u> 45:513-524 (1974)			
	*121	Epp et al., "The molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI refined at 2.0-A resolution" <u>Biochemistry</u> 14(22):4943-4952 (1975)			
	*122	Fahy et al., "The Effect of an Anti-IgE Monoclonal Antibody on the Early- and Late-Phase Responses to Allergen Inhalation in Asthmatic Subjects" <u>Am J. Respir. Crit. Care Med</u> 155:1828-1834 (1997)			
	*123	Fanger et al., "Bispecific antibodies and targeted cellular cytotoxicity" <u>Immunology Today</u> 12(2):51-54 (1991)			
	*124	Fanger et al., "Cytotoxicity mediated by human Fc receptors for IgG" <u>Immunology Today</u> 10(3):92-99 (1989)			
	*125	Feldmann et al., "A Hypothetical Space-Filling Model of the V-Regions of the Galactan-Binding Myeloma Immunoglobulin J539" <u>Molecular Immunology</u> 18(8):683-698 (1981)			
	*126	Fendley et al., "The Extracellular Domain of HER2/neu Is a Potential Immunogen for Active Specific Immunotherapy of Breast Cancer" <u>J. Biol. Resp. Mod.</u> 9:449-455 (1990)			
	*127	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (Mar 1, 1990)			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0709P1D3	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Paul J. Carter et al.	
				Filing Date 02 Nov 2000	Group not yet assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	*128	Foote et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops" <u>J. Mol. Biol.</u> 224:487-499 (1992)			
	*129	Foote, J., "Humanized Antibodies" <u>Nova acta Leopoldina</u> 61(269):103-110 (1989)			
	*130	Furey et al., "Structure of a novel Bence-Jones protein (Rhe) fragment at 1.6 A resolution" <u>J. Mol. Biol.</u> 167(3):661-692 (July 5, 1983)			
	*131	Glennie et al., "Preparation and Performance of Bispecific F(ab') ₂ Antibody Containing Thioether-Linked Fab'γ Fragments" <u>J. Immunol.</u> 139(7):2367-2375 (October 1, 1987)			
	*132	Gonzalez et al., "Humanization of Murine 6G425: An Anti-IL8 Monoclonal Antibody Which Blocks Binding of IL8 to Human Neutrophils" <u>1996 Keystone Symposia on Exploring and Exploiting Antibody and Ig Superfamily Combining Sites</u> (Poster) pps. 1-21 (February 1996)			
	*133	Gorman et al., "Reshaping a therapeutic CD4 antibody" <u>Proc. Natl. Acad. Sci. USA</u> 88(10):4181-4185 (May 15, 1991)			
	*134	Gregory et al., "The solution conformations of the subclasses of human IgG deduced from sedimentation and small angle X-ray scattering studies" <u>Molecular Immunology</u> 24(8):821-829 (August 1987)			
	*135	Gussow & Seemann, "Humanization of Monoclonal Antibodies" <u>Meth. Enzymology</u> , Academic Press, Inc. Vol. 203:99-121 (1991)			
	*136	Hale, G. et al., "Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H" <u>Lancet</u> 2(8625):1394-1399 (Dec 17, 1988)			
	*137	Harris et al., "Therapeutic Antibodies - The Coming of Age" <u>TIBTECH</u> 11:42-44 (February 1993)			
	*138	Hieter et al., "Cloned human and mouse kappa immunoglobulin constant and J region genes conserve homology in functional segments" <u>Cell</u> 22(Part 1):197-207 (1980)			
	*139	Hieter et al., "Evolution of Human Immunoglobulin K J Region Genes" <u>The Journal of Biological Chemistry</u> 257:1516-1522 (1982)			
	*140	Houghton, A., "Building a better monoclonal antibody" <u>Immunology Today</u> 9(9):265-267 (1988)			
	*141	Huber et al., "Crystallographic structure studies of an IgG molecule and an Fc fragment" <u>Nature</u> 264:415-420 (December 2, 1976)			
	*142	Hudziak et al., "p185HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Molecular & Cellular Biology</u> 9(3):1165-1172 (Mar 1989)			
	*143	Huston et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli" <u>Proc. Natl. Acad. Sci. USA</u> 85:5879-5883 (Aug 1988)			
	*144	Isaacs et al., "Humanised Monoclonal Antibody Therapy for Rheumatoid Arthritis" <u>Lancet</u> 340:748-752 (September 26, 1992)			
	*145	Jaffers et al., "Monoclonal Antibody Therapy, Anti-Idiotypic and Non-Anti-Idiotypic Antibodies to OKT3 Arising Despite Intense Immunosuppression" <u>Transplantation</u> 41(5):572-578 (May 1986)			
	*146	Johnson et al., "Biological and Molecular Modeling Studies Comparing Murine Monoclonal Antibodies with Their Engineered Chimeric and Humanized Counterparts" <u>J. Cell. Biochem. Suppl. 0 (13 Part A)</u> (18th Ann. UCLA Symp on Mol. & Cell. Biol., Park City, UT 1/17-22/89) pps. 87 (1989)			
	*147	Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

09/705/684

Sheet 07 of 13

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0709P1D3	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Paul J. Carter et al.	
				Filing Date 02 Nov 2000	Group not yet assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	*148	Junghans et al., "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders" <u>Cancer Research</u> 50(5):1495-1502 (March 1, 1990)			
	*149	Kabat E., "Origins of Antibody Complementarity and Specificity - Hypervariable Regions and the Minigenes Hypothesis" <u>J. of Immunology</u> 125(3):961-969 (Sep 1980)			
	*150	Kabat et al. <u>Sequences of Proteins of Immunological Interest</u> , Bethesda, MD:National Institutes of Health pps. iii-xxiii, 41-76 and 160-167 (1987)			
	*151	Kabat et al. <u>Sequences of Proteins of Immunological Interest</u> , U.S. Dept. of Health and Human Services, NIH, 5th edition Vol. 1:103-108, 324-331 (1991)			
	*152	Kabat et al., "Sequences of Proteins of Immunological Interest", Bethesda, MD:National Institute of Health pps. 14-32 (1983)			
	*153	Kabat et al., "Sequences of Proteins of Immunological Interest, 4th Edition" pps. iii-xxvii, 41-76, 160-175 (1987)			
	*154	Kettleborough et al., "Humanization of a Mouse Monoclonal Antibody by CDR-grafting: the Importance of Framework Residues on Loop Conformation" <u>Protein Engineering</u> 4(7):773-783 (1991)			
	*155	Kindt & Capra <u>The Antibody Enigma</u> , New York:Plenum Press pps. 79-86 (1984)			
	*156	King et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma" <u>Science</u> 229:974-976 (Sept 1985)			
	*157	Lazar et al., "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities" <u>Molecular & Cellular Biology</u> 8(3):1247-1252 (Mar. 1988)			
	*158	Lesk & Chothia, "Evolution of Proteins Formed by β -Sheets" <u>J. Mol. Biol.</u> 160:325-342 (1982)			
	*159	Lesk & Chothia, "The response of protein structures to amino-acid sequence changes" <u>Phil. Trans. R. Soc. Lond. A</u> 317:345-356 (1986)			
	*160	Lesk, Arthur M., "How Different Amino Acid Sequences Determine Similar Protein Structures: The Structure and Evolutionary Dynamics of the Globins" <u>J. Mol. Biol.</u> 136:225-270 (1980)			
	*161	Love et al., "Recombinant antibodies possessing novel effector functions" <u>Methods in Enzymology</u> 178:515-527 (1989)			
	*162	Lupu et al., "Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2" <u>Science</u> 249:1552-1555 (1990)			
	*163	Maeda et al., "Construction of Reshaped Human Antibodies with HIV-neutralizing Activity" <u>Hum. Antibod. Hybridomas</u> 2:124-134 (July 1991)			
	*164	Margni RA and Binaghi RA, "Nonprecipitating asymmetric antibodies" <u>Ann. Rev. Immunol.</u> 6:535-554 (1988)			
	*165	Margolies et al., "Diversity of light chain variable region sequences among rabbit antibodies elicited by the same antigens." <u>Proc. Natl. Acad. Sci. USA</u> 72:2180-84 (Jun 1975)			
	*166	Mariuzza et al., "The Structure Basis of Antigen-Antibody Recognition" <u>Ann. Rev. Biophys. Biophys. Chem</u> 16:139-159 (1987)			
	*167	Marquart et al., "Crystallographic refinement and atomic models of the intact immunoglobulin molecule Kol and its antigen-binding fragment at 3.0 A and 1.0 A resolution" <u>J. Mol. Biol.</u> 141(4):369-391 (Aug 25, 1980)			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0709P1D3	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Paul J. Carter et al.	
				Filing Date 02 Nov 2000	Group not yet assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	*168	Mathieson et al., "Monoclonal-Antibody Therapy in Systemic Vasculitis" <u>New England J. of Medicine</u> pps. 250-254 (July 1990)			
	*169	Matsumura et al., "Hydrophobic stabilization in T4 lysozyme determined directly by multiple substitutions of Ile 3" <u>Nature</u> 334:406-410 (1988)			
	*170	Mian, IS et al., "Structure, function and properties of antibody binding sites" <u>J. Mol. Biol.</u> 217(1):133-151 (Jan 5, 1991)			
	*171	Miller, R. et al., "Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma" <u>Blood</u> 62:988-995 (1983)			
	*172	Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains" <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (November 1984)			
	*173	Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies" <u>Science</u> 229:1202-1207 (September 20, 1985)			
	*174	Nadler et al., "Immunogenicity of Humanized and Human Monoclonal Antibodies" <u>Clin. Pharmacology & Therapeutics</u> pps. 180 (Feb 1994)			
	*175	Nakatani et al., "Humanization of mouse anti-human IL-2 receptor antibody B-B10" <u>Protein Engineering</u> 7:435-443 (1994)			
	*176	Nelson, H., "Targeted Cellular Immunotherapy with Bifunctional Antibodies" <u>Cancer Cells</u> 3:163-172 (1991)			
	*177	Neuberger et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function" <u>Nature</u> 314:268-270 (March 21, 1985)			
	*178	Neuberger et al., "Antibody Engineering" <u>Proceedings 8th Intl. Biotech. Symp., Paris</u> 11:792-799 (1988)			
	*179	Neuberger et al., "Recombinant Antibodies Possessing Novel Effector Functions" <u>Nature</u> 312:604-608 (December 13, 1984)			
	*180	Newmark, P., "Making Chimeric Antibodies Even More Human" <u>Bio/Technology</u> 6:468 (May 1988)			
	*181	Nishimura et al., "Human c-erbB-2 Proto-Oncogene Product as a Target for Bispecific-Antibody-Directed Adoptive Tumor Immunotherapy" <u>Int. J. Cancer</u> 50:800-804 (1992)			
	*182	Nitta et al., "Preliminary trial of specific targeting therapy against malignant glioma" <u>Lancet</u> 335(8686):368-371 (Feb 17, 1990)			
	*183	Nitta, T. et al., "Bispecific F(ab') ₂ monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytotoxicity of human T cells" <u>European Journal of Immunology</u> 19:1437-1441 (1989)			
	*184	Nolan et al., "Bifunctional antibodies: concept, production and applications" <u>Biochimica et Biophysica Acta</u> 1040:1-11 (1990)			
	*185	Novotny et al., "Structural invariants of antigen binding: comparison of immunoglobulin V _L -V _H and V _L -V _L domain dimers" <u>Proc. Natl. Acad. Sci. USA</u> 82(14):4592-4596 (Jul 1985)			
	*186	O'Connor et al., "Calcium Dependence of an Anti-Protein C Humanized Antibody Involves Framework Residues" (manuscript)			
	*187	Ohtomo et al., "Humanization of Mouse ONS-M21 Antibody with the Aid of Hybrid Variable Regions" <u>Molecular Immunology</u> 32:407-416 (1995)			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

09/7051684

Sheet 09 of 13

FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0709P1D3	Serial No. not yet assigned
				Applicant Paul J. Carter et al.	
				Filing Date 02 Nov 2000	
				Group not yet assigned	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
*188	Orlandi et al., "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction" <u>Proc. Natl. Acad. Sci. USA</u> 86:3833-3837 (May 1989)				
*189	Orlandi et al., "Cloning of cDNA Corresponding to Heavy and Light Chain Immunoglobulin Variable Domains" <u>Protein and Pharmaceutical Engineering</u> pps. 90 (1989)				
*190	Ostberg & Queen, "Human and humanized monoclonal antibodies: preclinical studies and clinical experience" <u>Biochem. Soc. Transactions</u> pps. 1038-1043 (1995)				
*191	Padlan et al., "Model-Building Studies of Antigen-Binding Sites: The Hapten-Binding Site of MOPC-315" <u>C.S. Harbor Symp. Quant. Biol.</u> 41:627-637 (1977)				
*192	Padlan et al., "Model-building Studies of Antigen-binding Sites: The Hapten-binding Site of MOPC-315" <u>Cold Springs Harbor Symposia On Quantitative Biology</u> XLI:627-637 (1977)				
*193	Padlan, E., "Anatomy of the Antibody Molecule" <u>Molecular Immunology</u> 31(3):169-217 (1994)				
*194	Padlan, E., "Evaluation of the Structural Variation Among Light Chain Variable Domains" <u>Molecular Immunology</u> 16:287-296 (1979)				
*195	Palm & Hilschmann, "Primary structure of a crystalline monoclonal immunoglobulin K-type L-chain, subgroup I (Bence-Jones preotin Rei); isolation & characterization of the tryptic peptides:..." <u>Hoppes-Sevler's Z. Physiol. Chem.</u> 356:167-191 (Feb 1975)				
*196	Palm & Hilschmann, "The primary structure of a crystalline, monoclonal immunoglobulin-L-chain of the x-type, subgroup I (Bence-Jones Protein Rei): a contribution to the elucidation of the three-dimensional structure of the immunoglobulins" <u>Hoppe-Sevler's Z. Physiol. Chem.</u> 354:1651-1654 (Dec 1973)				
*197	Panka et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 85:3080-3084 (May 1988)				
*198	Pluckthun, Andreas, "Antibody engineering: advances from the use of escherichia coli expression systems" <u>Biotechnology</u> 9:545-51 (1991)				
199	"Polygen Corporation" in New Products, Chemical Design Automation 3 (November 1988)				
*200	Presta et al., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders" <u>Cancer Research</u> 57(20):4593-4599 (Oct 15, 1997)				
*201	Presta et al., "Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders" <u>Cancer Research</u> (in press) pps. 1-32				
*202	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)				
*203	Preval & Fougereau, "Specific Interaction between V _H and V _L Regions of Human Monoclonal Immunoglobulins" <u>J. Mol. Biol.</u> 102:657-678 (1976)				
*204	Queen et al., "A humanized antibody that binds to the interleukin 2 receptor" <u>Proc. Natl. Acad. Sci. USA</u> 86(24):10029-10033 (December 1989)				
*205	Queen et al., "Construction of Humanized Antibodies and Testing in Primates" <u>J. Cell. Biochem. Suppl.</u> 1 (Part E) (20th Ann. Mtg. Keystone Symp. Denver, CO Mar 10-16, 1991) pps. 137 (1991)				
*206	Queen et al., "Humanised antibodies to the IL-2 receptor" <u>Protein Eng. Antibody Mol. Prophyl. Ther. Appl. Man.</u> Clark, M., Nottingham, UK: Academic Titles pps. 159-70 (1993)				
*207	Rhodes & Birch, "Large-Scale Production of Proteins from Mammalian Cells" <u>Bio/Technology</u> 6:518, 521, 52 (May 1988)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

09/705,684

Sheet 10 of 13

FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0709P1D3	Serial No. not yet assigned
				Applicant Paul J. Carter et al.	
				Filing Date 02 Nov 2000	
				Group not yet assigned	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
*208	Riechmann & Winter, "Recombinant Antibodies" (U. of London Royal Postgraduate Medical School, Wolfson Institute, Abstract) (May 1987)				
*209	Riechmann et al., "Expression of an Antibody Fv Fragment in Myeloma Cells" <u>J. Mol. Biol.</u> 203:825-828 (1988)				
*210	Riechmann et al. <u>Alignment of VL Sequences</u> (1988)				
*211	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988)				
*212	Riechmann, "Declaration" <u>from EP Opposition to EP Patent No. 451,261 B1</u> (Oct 22, 1996)				
*213	Riechmann, "Humanizing of Recombinant Antibodies" (Intl. Symp. on Clin. Appl. of Monoclonal Antibodies, Guildford, England) pps. 33-34 (Sep 1987)				
*214	Roberts & Rees, "Generation of an antibody with enhanced affinity and specificity for its antigen by protein engineering" <u>Nature</u> 328:731-734 (Aug 1987)				
*215	Rodrigues et al., "Engineering a humanized bispecific F(ab') ₂ fragment for improved binding to T cells" <u>Int. J. Cancer</u> (Suppl.) 7:45-50 (1992)				
*216	Roitt et al. <u>Immunology</u> (Gower Medical Publishing Ltd., London, England) pps. 5.5 (1985)				
*217	Rostapshov et al., "Effective method for obtaining long nucleotide chains on partially complementary templates" <u>FEBS Letters</u> 249(2):379-382 (Jun 1989)				
*218	Routledge et al., "A Humanized Monoclonal CD3 Antibody which Can Activate Homologous Complement" <u>European Journal of Immunology</u> 21:2717-2725 (1991)				
*219	Saul et al., "Preliminary refinement and structural analysis of the Fab fragment from human immunoglobulin new at 2.0 A resolution" <u>Journal of Biological Chemistry</u> 253(2):585-597 (January 25, 1978)				
*220	Schneider et al., "The Anti-Idiotypic Response by Cynomolgus Monkeys to Humanized Anti-Tac is Primarily Directed to Complementarity-Determining Regions H1, H2, and L3" <u>J. of Immunology</u> 150:3086-3090 (Apr 1993)				
*221	Schroff, R. et al., "Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy" <u>Cancer Research</u> 45:879-885 (1985)				
*222	Sedlacek et al., "Monoclonal Antibodies in Tumor Therapy", Karger pps. 119-126, 133-179 (1988)				
*223	Segal et al., "The three-dimensional structure of a phosphorylcholine-binding mouse immunoglobulin Fab and the nature of the antigen binding site" <u>Proc. Natl. Acad. Sci. USA</u> 71(11):4298-4302 (Nov 1974)				
*224	Sha et al., "A Heavy-Chain Grafted Antibody that Recognizes the Tumor-Associated TAG72 Antigen" <u>Cancer Biotherapy</u> 9:341-349 (1994)				
*225	Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene" <u>Journal of Experimental Medicine</u> 175:217-225 (Jan 1, 1992)				
*226	Shearman et al., "Construction, Expression and Characterization of Humanized Antibodies Directed Against the Human α/β T Cell Receptor" <u>J. Immunol.</u> 147(12):4366-4373 (December 15, 1991)				
*227	Shepard and Lewis, "Resistance of tumor cells to tumor necrosis factor" <u>J. Clin. Immunol.</u> 8(5):333-395 (1988)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

09/705,686

Sheet 11 of 13

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0709P1D3	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Paul J. Carter et al.	
				Filing Date 02 Nov 2000	Group not yet assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
*228	Sheriff et al., "Three-dimensional structure of an antibody-antigen complex" <u>Proc. Natl. Acad. Sci. USA</u> 84(22):8075-8079 (Nov. 1987)				
*229	Sherman et al., "Haloperidol binding to monoclonal antibodies" <u>Journal of Biological Chemistry</u> 263:4064-4074 (1988)				
*230	Shields et al., "Inhibition of Allergic Reactions with Antibodies to IgE" <u>International Archives of Allergy and Immunology</u> 107(1-3):308-312 (May 1995)				
*231	Silverton et al., "Three-dimensional structure of an intact human immunoglobulin" <u>Proc. Natl. Acad. Sci. USA</u> 74:5140-5144 (1977)				
*232	Sims et al., "A Humanized CD18 Antibody Can Block Function Without Cell Destruction" <u>The Journal of Immunology</u> 151(4):2296-2308 (Aug 1993)				
*233	Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> 235:177-182 (Jan 9, 1987)				
*234	Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer" <u>Science</u> 244:707-712 (May 12, 1989)				
*235	Smith-Gill et al., "A Three-dimensional Model of an Anti-lysozyme Antibody" <u>Mol. Biol.</u> 194:713-724 (1987)				
*236	Snow and Amzel, "Calculating three-dimensional changes in protein structure due to amino-acid substitutions: the variable region of immunoglobulins" <u>Protein: Structure, Function, and Genetics</u> , Alan R. Liss, Inc. Vol. 1:267-279 (1986)				
*237	Songsivilai et al., "Bispecific antibody: a tool for diagnosis and treatment of disease" <u>Clin. Exp. Immunol.</u> 79:315-321 (1990)				
*238	Sox et al., "Attachment of carbohydrate to the variable region of myeloma immunoglobulin light chains" <u>Proc. Natl. Acad. Sci. USA</u> 66:975-82 (July 1970)				
*239	Spiegelberg et al., "Localization of the carbohydrate within the variable region of light and heavy chains of human γ G myeloma proteins" <u>Biochemistry</u> 9:4217-23 (Oct 1970)				
*240	Stanford, "A Predictive Method for Determining Possible Three-dimensional Foldings of Immunoglobulin Backbones Around Antibody Combining Sites" <u>Theor. Biol.</u> 88:421-439 (1981)				
*241	Stickney et al., "Bifunctional Antibody: ZCE/CHA ¹¹¹ Indium BLEDTA-IV Clinical Imaging in Colorectal Carcinoma" <u>Antibody, Immuno Radiopharm</u> 2:1-13 (1989)				
*242	Takeda et al., "Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequences" <u>Nature</u> 314(6010):452-454 (April 4, 1985)				
*243	Tao et al., "Studies of aglycosylated chimeric mouse-human IgG. Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region" <u>Journal of Immunology</u> 143(8):2595-2601 (Oct 15, 1989)				
*244	Tempest et al., "Identification of framework residues required to restore antigen binding during reshaping of a monoclonal antibody against the glycoprotein gB of human cytomegalovirus" <u>Int. J. Biol. Macromol.</u> 17:37-42 (1995)				
*245	Tempest et al., "Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection In Vivo" <u>Bio/Technology</u> 9:266-271 (March 1991)				
*246	Tighe et al., "Delayed Allograft Rejection in Primates Treated with Anti-IL-2 Receptor Monoclonal antibody Campath-6" <u>Transplantation</u> 45(1):226-228 (Jan 1988)				
*247	Tramontano et al., "Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the V _H domains of immunoglobulins" <u>J. Mol. Biol.</u> 215(1):175-182 (Sep 5, 1990)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

09/705,686

Sheet 12 of 13

FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0709P1D3	Serial No. not yet assigned
				Applicant Paul J. Carter et al.	
				Filing Date 02 Nov 2000	
				Group not yet assigned	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
*248	Tramontano, "Structural Determinants of the Conformations of Medium-Sized Loops in Proteins" <u>Proteins</u> 6:382-394 (1989)				
*249	Uchiyama et al., "A Monoclonal Antibody (ANTI-Tac) Reactive with Activated and Functionally Mature Human T Cells" <u>Journal of Immunology</u> 126:1393-1397 (1981)				
*250	Verhoeyen & Riechmann, "Engineering of Antibodies" <u>BioEssays</u> 8(2):74-78 (Feb/Mar 1988)				
*251	Verhoeyen et al., "Grafting Hypervariable Regions in Antibodies" <u>Protein Structure, Folding, and Design</u> 2 (Proc. DuPont-UCLA Symp. Steamboat Springs, CO, Apr 4-11, 1987), Dale L. Oxender, New York: Alan R. Liss, Inc. pps. 501-502 (1987)				
*252	Verhoeyen et al., "Humanising Mouse Antibodies: A Protein Engineering Approach" <u>Soc. for Analytical Cytology</u> (XIIth Intl. Mtg. for the Soc. for Analytical Cytology, Cambridge, UK) pps. 22 and slide presented at mtg				
*253	Verhoeyen et al., "Re-shaped human anti-PLAP antibodies" <u>Monoclonal Antibodies Applications in clinical oncology</u> , Epenetos, 1st edition, Chapman & Hall Medical pps. 37-43 (1991)				
*254	Verhoeyen et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)				
*255	Vincenti et al., "Interleukin-2-Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation" <u>New Engl. J. Med.</u> 338:161-165 (1998)				
*256	Vitetta et al., "Redesigning Nature's Poisons to Create Anti-Tumor Reagents" <u>Science</u> 238:1098-1104 (1987)				
*257	Waldmann et al., "Interleukin 2 Receptor (Tac Antigen) Expression in HTLV-1-associated Adult T-Cell Leukemia" <u>Cancer Research</u> 45:4559s-4562s (1985)				
*258	Waldmann, T., "Monoclonal Antibodies in Diagnosis and Therapy" <u>Science</u> 252:1657-1662 (June 1991)				
*259	Waldmann, Thomas A., "The Structure, Function, and Expression of Interleukin-2 Receptors on Normal and Malignant Lymphocytes" <u>Science</u> 232:727-732 (1986)				
*260	Wallick et al., "Glycosylation of a VH residue of a monoclonal antibody against alpha (1---6) dextran increases its affinity for antigen" <u>Journal of Experimental Medicine</u> 168(3):1099-1109 (Sep 1988)				
*261	Ward et al., "Expression and Secretion of Repertoires of VH Domains in Escherichia Coli: Isolation of Antigen Binding Activities" <u>Progress in Immunology</u> (7th Intl. Congress Immunol. Berlin, W. Germany), F. Melchers Vol. VII:1144-1151 (1989)				
*262	Ward, E.S. et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli" <u>Nature</u> 341:544-546 (1989)				
*263	Werther et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1" <u>J. of Immunology</u> 157:4986-4995 (1996)				
*264	Whittle et al., "Construction and Expression of A CDR-Grafted Anti-TNF Antibody" <u>J. Cell Biochem. Suppl</u> Q (Symp. on Protein and Pharm. Eng. Mol. and Cell. Biol. Park City, Utah) 13 Part A:96 (1989)				
*265	Winter & Neuberger, "Restructuring Enzymes and Antibodies" <u>Investigation and Exploitation of Antibody Combining Sites</u> , Eric Reid, Plenum Press pps. 139-140 (1985)				
*266	Winter and Milstein, "Man-made antibodies" <u>Nature</u> 349(6307):293-299 (Jan 24, 1991)				
*267	Winter et al., "Protein Engineering by Site Directed Mutagenesis" <u>Chemical Synthesis in Molecular Biology</u> , H. Blocker et al., VCH pps. 189-197 (1987)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

USCOMM-DC 80-398.